What's Hot

View all perspectives
      RT @RichardPAConway: Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expe

      Richard Conway RichardPAConway

      2 years 5 months ago
      Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ
      RT @Janetbirdope: Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, a

      Janet Pope Janetbirdope

      2 years 5 months ago
      Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷‍♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t
      RT @RichardPAConway: Norwich regimen of steroids for GCA @cmukhtyar et al. Bespoke regime starting at 1mg/kg tapered ove

      Richard Conway RichardPAConway

      2 years 5 months ago
      Norwich regimen of steroids for GCA @cmukhtyar et al. Bespoke regime starting at 1mg/kg tapered over 100 weeks. Drug-free relapse free survival 82% at 100 weeks, 69% 150 weeks. @RheumNow #EULAR2022 POS0793 https://t.co/b5smCqCkgg
      RT @drdavidliew: Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue bey

      David Liew drdavidliew

      2 years 5 months ago
      Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU
      RT @Janetbirdope: Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by

      Janet Pope Janetbirdope

      2 years 5 months ago
      Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by pt factors - pt global and pain, skin, joints, CRP, function drove the data. Ask pt and treat what is treatable. #OP0025 @eular @RheumNow https://t.co/x4T6sPEi8o
      RT @Janetbirdope: Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and

      Janet Pope Janetbirdope

      2 years 5 months ago
      Cdn cohort of #PsA and CV events - u risk factors were associated with MACE and NSAIDS ⬆️ risk and TNFi ⬇️risk and poor HAQ⬆️ risk. #OP0030 @RheumNow @eular_org Too small events, lipids often absent and spanning 30+ yrs.
      RT @ericdeinmd: #EULAR OP0072: SMILE: Self-Management Individualised Learning Environment for RA
      😀5 modules, with 3-4

      Eric Dein ericdeinmd

      2 years 5 months ago
      #EULAR OP0072: SMILE: Self-Management Individualised Learning Environment for RA 😀5 modules, with 3-4 more planned in 2022 😀Learning objectives 😀Plan to target resources to questionnaire @RheumNow
      RT @AurelieRheumo: Behcet disease:
      RCT Topical Tacrolimus for mouth ulcers in 40+pts
      ↘️VAS 2 wks & 3mo
      ↘️ N

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      Behcet disease: RCT Topical Tacrolimus for mouth ulcers in 40+pts ↘️VAS 2 wks & 3mo ↘️ Number of ulcers ↘️ Ulcer size and duration ↘️ Ulcer severity score #OP0046 #EULAR2022 @RheumNow
      RT @AurelieRheumo: SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA
      as expected:
      ↘️disease activity
      ↘️pain and

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA as expected: ↘️disease activity ↘️pain and function ↘️QoL at 14 wks no new safety alerts https://t.co/2efpx7Mi6i
      RT @AurelieRheumo: AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest. German GESPIC AxPsA cohort: *More frequently 🚺 *Less frequently B27+ *20% isolated Ax involvement @Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J
      RT @RichardPAConway: Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #

      Richard Conway RichardPAConway

      2 years 5 months ago
      Long-term canakinumab data in FMF from RELIANCE registry. 63% in remission at month 24. @RheumNow #EULAR2022 OP0042 https://t.co/mEIoAszmZq https://t.co/IvR1cSG4Aq
      RT @RichardPAConway: Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on

      Richard Conway RichardPAConway

      2 years 5 months ago
      Can be challenging to identify early/impending MAS in AoSD. Ruscitti et al propose a model based on systemic score, ferritin, IFN-γ, and IL-10 with AUC 0.99, sensitivity 100% specificity 95% @RheumNow #EULAR2022 OP0044 https://t.co/bbWkdGCnHP
      RT @RichardPAConway: More from the VITAL study Dr Costenbader @karen_kc123 et al. 5 year supplementation followed 2 year

      Richard Conway RichardPAConway

      2 years 5 months ago
      More from the VITAL study Dr Costenbader @karen_kc123 et al. 5 year supplementation followed 2 year follow up. Vit D 2000iu ⬇️incident autoimmune disease 21%. RA, PMR, psoriasis trend towards reduction. No effect omega-3 @RheumNow #EULAR2022 OP0038 https://t.co/kbKqDhtN9z https://t.co/HcFXbweEPm
      RT @KDAO2011: Severe heme relapses are common in #SLE pts w/prior severe heme episodes: ATTIKON SLE cohort 800 pts
      👉1

      TheDaoIndex KDAO2011

      2 years 5 months ago
      Severe heme relapses are common in #SLE pts w/prior severe heme episodes: ATTIKON SLE cohort 800 pts 👉13% w/severe heme dz: TMA, MAS, plt < 30K, hemolysis hgb < 8 👉heme issues preceded SLE dx in 1/3 of pts 👉>50% pts had severe heme flare 👉0 deaths #EULAR2022 @rheumnow POS0116
      RT @KDAO2011: Low rates of hypersensitivity reactions (HSR) to #anifrolumab
      Pooled data MUSE &amp; TULIP-1/-2 w/1100 pts

      TheDaoIndex KDAO2011

      2 years 5 months ago
      Low rates of hypersensitivity reactions (HSR) to #anifrolumab Pooled data MUSE & TULIP-1/-2 w/1100 pts: 👉1 anaphylaxis (0.15%) 👉12 HSR (3%) 👉43 infusion reaction (9%): N/V/headache 👉most easily treatable w/antihistamine, GCs, acetaminophen #EULAR2022 POS0708 @rheumnow

      Podcasts

      • ACR24 SpA Topic Panel Key Discussions on Spondyloarthritis
      • ACR24 - RHEUMATOID ARTHRITIS
      • ACR24 - IL - 17

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.